Wall Street analyst estimates for Dogwood Therapeutics, Inc. (DWTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.15 | ||
| 2026-08-13 | $-0.34 | $-0.14 | -142.9% |
| 2026-05-14 | $-0.15 | $-0.22 | +31.8% |
| 2026-03-18 | $-0.26 | $-0.86 | +69.8% |
| 2025-11-06 | $-8.20 | $-1.23 | -566.7% |
| 2025-08-13 | $-1.99 | $-1.26 | -57.9% |
| 2025-05-08 | $-8.45 | $-0.77 | -997.4% |
| 2025-02-26 | $-5.90 | $-1.36 | -333.6% |
Valuation Ratios
| Price / Book | 0.76 |
| EV / EBITDA | -2.30 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $854109 | $800620 | $194013 | $10.8M | $8.1M | $1.7M | $3.5M | $21.9M |
| Selling, General & Admin | $1.1M | $1.4M | $9.8M | $4.8M | $4.2M | $3.7M | $8.7M | $6.1M |
| Operating Expenses | $2.0M | $2.2M | $10.0M | $15.6M | $12.3M | $5.4M | $12.2M | $28.0M |
| Operating Income | -$2.0M | -$2.2M | -$10.0M | -$15.6M | -$12.3M | -$5.4M | -$12.2M | -$28.0M |
| EBITDA | -$2.0M | -$2.2M | -$10.0M | -$16.0M | -$12.2M | -$5.3M | -$12.2M | -$34.0M |
| Interest Expense | $152103 | $295128 | $384222 | 0 | 0 | 0 | $92192 | 0 |
| Pre-tax Income | -$2.1M | -$2.5M | -$10.3M | -$16.0M | -$12.2M | -$5.3M | -$12.4M | -$34.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -$503 | $221096 |
| Net Income | -$2.1M | -$2.5M | -$10.3M | -$16.0M | -$12.2M | -$5.3M | -$12.3M | -$34.3M |
| EPS | $-10.93 | $-12.80 | $-52.50 | $-47.90 | $-27.66 | $-7.05 | $-12.52 | $-4.32 |
| EPS (Diluted) | $-10.93 | $-12.80 | $-52.50 | $-47.90 | $-27.66 | $-7.05 | $-12.52 | $-4.32 |
| Shares Outstanding (Diluted) | $193299 | $193299 | $197079 | $333172 | $442804 | $751071 | $1.0M | $8.2M |
Price
| Price | $1.70 |
| Market Cap | $57M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BOLT · BRTX · CLRB · COCP · EDSA · ERNA · EVGN
Explore sector: Healthcare · Biotechnology
More sections of DWTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks